Hepatosplenic T-Cell Lymphoma Terminated Phase 2 Trials for Nivolumab (DB09035)

Also known as: Alpha-beta and gamma delta types

IndicationStatusPhase
DBCOND0040132 (Hepatosplenic T-Cell Lymphoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03075553Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaTreatment